P-01-008 Cross-sex hormone treatment and psychobiological changes in transsexual persons: Two-year follow-up data

2017 ◽  
Vol 14 (4) ◽  
pp. e163-e164
Author(s):  
A.D. Fisher ◽  
G. Castellini ◽  
J. Ristori ◽  
H. Casale ◽  
E. Cassioli ◽  
...  
Keyword(s):  
Hormone Treatment ◽  
Sex Hormone

PS-02-005 Cross-sex hormone treatment and psychobiological changes in transsexual persons: 2-years follow-up data

2016 ◽  
Vol 13 (5) ◽  
pp. S84-S85
Author(s):  
A.D. Fisher ◽  
G. Castellini ◽  
E. Fanni ◽  
H. Casale ◽  
A.L. Amato ◽  
...  
Keyword(s):  
Hormone Treatment ◽  
Sex Hormone

scholarly journals Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data

2016 ◽  
Vol 101 (11) ◽  
pp. 4260-4269 ◽  
Author(s):  
Alessandra D. Fisher ◽  
Giovanni Castellini ◽  
Jiska Ristori ◽  
Helen Casale ◽  
Emanuele Cassioli ◽  
...  
Keyword(s):  
Hormone Treatment ◽  
Sex Hormone

scholarly journals Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence

2014 ◽  
Vol 11 (8) ◽  
pp. 1999-2011 ◽  
Author(s):  
Katrien Wierckx ◽  
Eva Van Caenegem ◽  
Thomas Schreiner ◽  
Ira Haraldsen ◽  
Alessandra Fisher ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Sex Hormone ◽  
European Network ◽  
In Trans ◽  
Short Time

scholarly journals Cross-sex hormone treatment and own-body perception: behavioral and brain connectivity profiles

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Behzad S. Khorashad ◽  
Amirhossein Manzouri ◽  
Jamie D. Feusner ◽  
Ivanka Savic
Keyword(s):  
Brain Connectivity ◽  
Hormone Treatment ◽  
Sex Hormone ◽  
Anterior Cingulate ◽  
Angular Gyrus ◽  
Group Differences ◽  
Body Perception ◽  
Functional Connections ◽  
Before And After ◽  
Superior Parietal Cortex

AbstractReferrals for gender dysphoria (GD), characterized by a distressful incongruence between gender identity and at-birth assigned sex, are steadily increasing. The underlying neurobiology, and the mechanisms of the often-beneficial cross-sex hormone treatment are unknown. Here, we test hypothesis that own body perception networks (incorporated in the default mode network—DMN, and partly in the salience network—SN), are different in trans-compared with cis-gender persons. We also investigate whether these networks change with cross-sex hormone treatment. Forty transmen (TrM) and 25 transwomen (TrW) were scanned before and after cross-sex hormone institution. We used our own developed Body Morph test (BM), to assess the perception of own body as self. Fifteen cisgender persons were controls. Within and between-group differences in functional connectivity were calculated using independent components analysis within the DMN, SN, and motor network (a control network). Pretreatment, TrM and TrW scored lower “self” on the BM test than controls. Their functional connections were weaker in the anterior cingulate-, mesial prefrontal-cortex (mPFC), precuneus, the left angular gyrus, and superior parietal cortex of the DMN, and ACC in the SN “Self” identification and connectivity in the mPFC in both TrM and TrW increased from scan 1 to 2, and at scan 2 no group differences remained. The neurobiological underpinnings of GD seem subserved by cerebral structures composing major parts of the DMN.

scholarly journals Disorders of gender identity: what to do and who should do it?

2014 ◽  
Vol 204 (2) ◽  
pp. 96-97 ◽  
Author(s):  
James Barrett
Keyword(s):  
Primary Care ◽  
Gender Identity ◽  
Gender Role ◽  
Treatment Plan ◽  
Hormone Treatment ◽  
Sex Hormone ◽  
Early Referral ◽  
Sustained Improvement ◽  
Social State ◽  
Gender Reassignment

SummaryTranssexualism is not usually indicative of psychopathology. In carefully selected individuals, with multidisciplinary support, a change of social gender role and cross-sex hormone treatment greatly improves the psychological and social state. Sustained improvement merits gender reassignment surgery. The key is early referral with subsequent primary care cooperation in the treatment plan.

COMPARISON OF ARTIFICIAL INSEMINATION AND NATURAL MATING ON REPRODUCTIVE PERFORMANCE OF FIVE STRAINS OF SHEEP DURING THE ANESTROUS SEASON IN AN INTENSIVE SYSTEM

1979 ◽  
Vol 59 (4) ◽  
pp. 675-683 ◽  
Author(s):  
A. J. HACKETT ◽  
H. A. ROBERTSON ◽  
E. K. INSKEEP ◽  
J. N. B. SHRESTHA ◽  
M. S. WOLYNETZ
Keyword(s):  
Reproductive Performance ◽  
Artificial Insemination ◽  
Hormone Treatment ◽  
Corpora Lutea ◽  
Blood Samples ◽  
Natural Mating ◽  
Main Effects ◽  
Mating Method ◽  
Intensive System

Synchronized estrus and ovulation were induced during the anestrous season (April–May 1974) in 373 ewes of three synthetic (one sire and two dam) strains and two unselected (Suffolk and Finnish Landrace) purebred strains by treatment with 30 mg fluorogestone acetate (FGA) impregnated in polyurethane intravaginal sponges for 12 days. Following sponge removal each ewe received 500 IU pregnant mares’ serum gonadotrophin (PMSG) IM. Of these, 167 were bred by artificial insemination (AI) at 48 and 60 h post sponge removal with 0.2 ml raw unextended semen collected by electroejaculation (EE). Five days after AI, ewes were exposed to a follow up ram for 16 days for subsequent mating if a second estrus occurred. The remaining 206 were exposed to rams for a period of 22 days for natural mating. Blood samples were collected from 69 ewes, 9, 19 and 27 days post sponge removal and analyzed for progesterone to ascertain if corpora lutea were formed and whether the ewes recycled. The age of ram by mating method interaction significantly affected both fertility and fecundity mainly because some of the younger rams lacked libido and experience for natural mating. There were no significant differences in prolificacy due to any of the main effects tested. Among the 69 ewes examined for progesterone levels, 93% had formed corpora lutea after hormone treatment and 16% recycled. Only 16 of the 255 ewes that did not conceive to the synchronized estrus lambed to the subsequent estrus.

scholarly journals Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study

2018 ◽  
Vol 215 (3) ◽  
pp. 519-527 ◽  
Author(s):  
Divya Mehta ◽  
Monika Rex-Haffner ◽  
Helle Bach Søndergaard ◽  
Anja Pinborg ◽  
Elisabeth B. Binder ◽  
...  
Keyword(s):  
Gene Expression ◽  
Dna Methylation ◽  
Depressive Symptoms ◽  
Perinatal Depression ◽  
Sex Hormone ◽  
Sex Steroid ◽  
Mood Changes ◽  
Induced Mood ◽  
Pharmacological Model

BackgroundEnhanced sensitivity to oestrogen signalling may drive increased risk for depressive symptoms when exposed to peripartum sex-steroid hormone fluctuations.AimTesting if 116 pre-identified sex steroid-responsive transcripts that predicted perinatal depression (PND) translates to a pharmacological model of hormone-induced mood changes.MethodWe generated longitudinal, genome-wide gene-expression and DNA-methylation data from 60 women exposed to a gonadotrophin-releasing hormone agonist (GnRHa) or placebo. We used linear mixed-effect models to assess differences between baseline and follow-up for gene expression and DNA methylation in the biphasic ovarian response to GnRHa.ResultsOf the 116 PND-predictive transcripts, a significant (19%) overlap was observed with those differentially expressed post-GnRHa at both early and later follow-up, indicating sustained effects. Similarly, 49% of tested genes were differentially methylated post-GnRHa at the late follow-up. Within the GnRHa group, a large proportion of PND genes were significantly associated (gene expression; DNA methylation) with changes in depressive symptoms (28%; 66%), oestradiol levels (49%; 66%) and neocortex serotonin transporter binding (8%; 45%) between baseline and follow-up.ConclusionsOur data bridge clinical PND biomarkers with a pharmacological model of sex hormone-induced mood changes and directly relate oestrogen-induced biological changes with depressive symptoms and associated serotonin-signalling changes. Our data highlight that individual variations in molecular sensitivity to oestrogen associate with susceptibility to hormone-induced mood changes and hold promise for candidate biomarkers.Declaration of interestV.G.F. received honorarium for being a speaker for H. Lundbeck A/S. E.B.B. receives research funding from Böhringer Ingelheim to investigate FKBP5 as a potential drug target for depression.

Sign in / Sign up

Export Citation Format

Share Document